These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 11149728)

  • 1. Donor leukocyte infusions for multiple myeloma.
    Salama M; Nevill T; Marcellus D; Parker P; Johnson M; Kirk A; Porter D; Giralt S; Levine JE; Drobyski W; Barrett AJ; Horowitz M; Collins RH
    Bone Marrow Transplant; 2000 Dec; 26(11):1179-84. PubMed ID: 11149728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Donor leukocyte infusions for recurrent hematologic malignancies after allogeneic bone marrow transplantation: impact of infused and residual donor T cells.
    Verdonck LF; Petersen EJ; Lokhorst HM; Nieuwenhuis HK; Dekker AW; Tilanus MG; de Weger RA
    Bone Marrow Transplant; 1998 Dec; 22(11):1057-63. PubMed ID: 9877267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Donor leukocyte infusions in acute lymphocytic leukemia.
    Collins RH; Goldstein S; Giralt S; Levine J; Porter D; Drobyski W; Barrett J; Johnson M; Kirk A; Horowitz M; Parker P
    Bone Marrow Transplant; 2000 Sep; 26(5):511-6. PubMed ID: 11019840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity.
    Peggs KS; Mackinnon S; Williams CD; D'Sa S; Thuraisundaram D; Kyriakou C; Morris EC; Hale G; Waldmann H; Linch DC; Goldstone AH; Yong K
    Biol Blood Marrow Transplant; 2003 Apr; 9(4):257-65. PubMed ID: 12720218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in T cell receptor repertoire associated with graft-versus-tumor effect and graft-versus-host disease in patients with relapsed multiple myeloma after donor lymphocyte infusion.
    Orsini E; Alyea EP; Schlossman R; Canning C; Soiffer RJ; Chillemi A; Neuberg D; Anderson KC; Ritz J
    Bone Marrow Transplant; 2000 Mar; 25(6):623-32. PubMed ID: 10734296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy with donor leukocyte infusions for patients with relapsed acute myeloid leukemia following partially mismatched related donor bone marrow transplantation.
    Pati AR; Godder K; Lamb L; Gee A; Henslee-Downey PJ
    Bone Marrow Transplant; 1995 Jun; 15(6):979-81. PubMed ID: 7581101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Donor T-lymphocyte infusion for unrelated allogeneic bone marrow transplantation with CD3+ T-cell-depleted graft.
    Lee CK; deMagalhaes-Silverman M; Hohl RJ; Hayashi M; Buatti J; Wen BC; Schlueter A; Strauss RG; Gingrich RD
    Bone Marrow Transplant; 2003 Jan; 31(2):121-8. PubMed ID: 12621494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Donor leukocyte infusions inducing remissions repeatedly in a patient with recurrent multiple myeloma after allogeneic bone marrow transplantation.
    van der Griend R; Verdonck LF; Petersen EJ; Veenhuizen P; Bloem AC; Lokhorst HM
    Bone Marrow Transplant; 1999 Jan; 23(2):195-7. PubMed ID: 10197809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease.
    Posthuma EF; Marijt EW; Barge RM; van Soest RA; Baas IO; Starrenburg CW; van Zelderen-Bhola SL; Fibbe WE; Smit WM; Willemze R; Falkenburg JH
    Biol Blood Marrow Transplant; 2004 Mar; 10(3):204-12. PubMed ID: 14993886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Graft-versus-lymphoma effect of donor lymphocyte infusion in indolent lymphomas relapsed after allogeneic stem cell transplantation.
    Mandigers CM; Verdonck LF; Meijerink JP; Dekker AW; Schattenberg AV; Raemaekers JM
    Bone Marrow Transplant; 2003 Dec; 32(12):1159-63. PubMed ID: 14647270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemotherapy does not nullify the ability of donor lymphocyte infusions to mediate graft-versus-host reactions.
    Fuchs EJ; Seber A; Altomonte V; Braine HG; Humphrey RL; Jones RJ; Noga SJ; Schepers K; Wright SK; Vogelsang GB
    Bone Marrow Transplant; 1998 Aug; 22(3):303-5. PubMed ID: 9720749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Allogeneic bone marrow transplantation for refractory multiple myeloma: presence of a graft-versus-myeloma effect].
    Nawa Y; Noguchi T; Kojima K; Hara M
    Rinsho Ketsueki; 2001 Jun; 42(6):481-7. PubMed ID: 11505527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expansion of tumor-specific CD8+ T cell clones in patients with relapsed myeloma after donor lymphocyte infusion.
    Orsini E; Bellucci R; Alyea EP; Schlossman R; Canning C; McLaughlin S; Ghia P; Anderson KC; Ritz J
    Cancer Res; 2003 May; 63(10):2561-8. PubMed ID: 12750280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors predicting response and graft-versus-host disease after donor lymphocyte infusions: a study on 593 infusions.
    Raiola AM; Van Lint MT; Valbonesi M; Lamparelli T; Gualandi F; Occhini D; Bregante S; di Grazia C; Dominietto A; Soracco M; Romagnani C; Vassallo F; Casini M; Bruno B; Frassoni F; Bacigalupo A
    Bone Marrow Transplant; 2003 Apr; 31(8):687-93. PubMed ID: 12692609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prophylactic donor lymphocyte infusions after moderately ablative chemotherapy and stem cell transplantation for hematological malignancies: high remission rate among poor prognosis patients at the expense of graft-versus-host disease.
    de Lima M; Bonamino M; Vasconcelos Z; Colares M; Diamond H; Zalcberg I; Tavares R; Lerner D; Byington R; Bouzas L; da Matta J; Andrade C; Carvalho L; Pires V; Barone B; Maciel C; Tabak D
    Bone Marrow Transplant; 2001 Jan; 27(1):73-8. PubMed ID: 11244440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of relapsed acute lymphoblastic leukemia after allogeneic bone marrow transplantation with chemotherapy followed by G-CSF-primed donor leukocyte infusion: a prospective study.
    Choi SJ; Lee JH; Lee JH; Kim S; Lee YS; Seol M; Ryu SG; Lee JS; Kim WK; Jang S; Park CJ; Chi HS; Lee KH
    Bone Marrow Transplant; 2005 Jul; 36(2):163-9. PubMed ID: 15937507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study of high-stringency CD8 depletion of donor leukocyte infusions after allogeneic hematopoietic stem cell transplantation.
    Orti G; Lowdell M; Fielding A; Samuel E; Pang K; Kottaridis P; Morris E; Thomson K; Peggs K; Mackinnon S; Chakraverty R
    Transplantation; 2009 Dec; 88(11):1312-8. PubMed ID: 19996931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adoptive immunotherapy with donor lymphocyte infusions and interleukin-2 after high-dose therapy and autologous stem cell rescue for multiple myeloma.
    Ballester OF; Fang T; Raptis A; Ballester G; Wilcox P; Hiemenz J; Tan B
    Bone Marrow Transplant; 2004 Sep; 34(5):419-23. PubMed ID: 15286696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discrepancy between serological complete remission and concomitant new bone lytic lesions after infusion of escalating low doses of donor lymphocytes in multiple myeloma: a case report.
    Rondelli D; Bandini G; Cavo M; Re F; Motta M; Senese B; Leopardi G; Stanzani M; Tura S
    Bone Marrow Transplant; 1999 Sep; 24(6):685-7. PubMed ID: 10490737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of relapse after allogeneic BMT with donor leukocyte infusions in 16 patients.
    Russell LA; Jacobsen N; Heilmann C; Simonsen AC; Christensen LD; Vindelov LL
    Bone Marrow Transplant; 1996 Aug; 18(2):411-4. PubMed ID: 8864454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.